To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed. A minimum of 38 patients will be recruited and randomized (1:1) to receive either verum or placebo. Lanreotide is already used in other disease states and found to be safe and non-toxic.

Inclusion Criteria:

• 18 yrs-of age
• Multiple cysts > 20
• Cooperating patient
• Is willing and able to comply with the study drug regimen and all other study requirements
• Willingness to give written informed consent

Exclusion Criteria:

• Use of oral anticonceptives or estrogen suppletion
• Females who are pregnant or breast-feeding
• History or other evidence of chronic pulmonary disease associated with functional limitation
• History of severe cardiac disease
• History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
• Symptomatic gallstones
• Renal failure requiring hemodialysis